Two distinct subgroups were identified: type I (37%), with TP53 and STK11/KEAP1 alterations, being similar to NSCLC, and type II (42%), similar with SCLC, which presents with the inactivation of TP53 and RB1 and also an upregulation of the immune-related pathways [9]. This evidence concerns the gene TP53 and small cell lung carcinoma.